Board of Directors

Steven Girgenti is a veteran healthcare executive with a foundation of expertise in healthcare marketing strategies, financing and mergers and acquisitions. Steve has been Executive Chairman of bioAffinity Technologies, Inc. since November 2014. He is presently the Managing Partner of Medi-Pharm Consulting, LLC providing strategic services to medical device, pharmaceutical and diagnostic businesses. Steve was formerly CEO and co-founder of DermWorx Incorporated, a dermatology company that specialized in developing nanotechnology formulations to enhance the performance of topical drugs. Mr. Girgenti was also the founder and CEO of Healthworld Corporation until 2008, a leading global healthcare marketing services network with 55 offices in 36 countries. The network had more than 1,000 brand assignments from nearly 200 clients worldwide, providing strategic marketing and communications services to many of the world’s leading healthcare companies. Mr. Girgenti founded Healthworld in 1986 and, under his leadership, the company made numerous acquisitions to expand and diversify the business. Healthworld went public in 1997. In 1998, and again in 1999, Business Week named Healthworld one of the “Best Small Corporations in America”. In 1999, Forbes listed Healthworld as one of the “200 Best Small Companies”. Mr. Girgenti was recognized as “Entrepreneur of the Year” by NASDAQ in 1999, and was named Med Ad News’ first “Medical Advertising Man of the Year” in 2000. In 2010 he was inducted into the Medical Advertising Hall of Fame. In addition, Mr. Girgenti is Vice Chairman of the Board of Governors for the Mt. Sinai Hospital Prostate Disease and Research Center in New York City, and is on the Board of Directors for the Jack Martin Fund, a Mt. Sinai Hospital affiliated charitable organization devoted to pediatric oncology research. He graduated from Columbia University and has worked in the pharmaceutical industry since 1968 for companies such as Bristol-Myers Squibb, Carter Wallace and DuPont.

Mr. Anderson has more than 40 years of broad experience the healthcare industry in which he held executive positions at CIBA, Becton Dickinson, Pfizer, Warner Lambert-Parke-Davis, Schering Plough and Centocor. Mr. Anderson was Vice-President of Marketing for the Key Pharmaceuticals division of Schering-Plough and later at Centocor, a worldwide healthcare company now owned by Johnson & Johnson. Mr. Anderson sat on the Executive Committee of Physicians World Communications Group (PWCG), where he was appointed as a Partner and Chief Operating Officer of the Company. Mr. Anderson currently provides Executive Management services to a number of CEOs of healthcare companies. Mr. Anderson received a B.A. in political science from Rutgers University and is a MENSA member.

Stuart Diamond is the Global Chief Financial Officer for GroupM, the world’s leading media investment company responsible for over $50 billion in media investment through agencies Mindshare, MediaCom, Wavemaker, Essence and m/SIX, as well as the outcomes-driven programmatic audience company, Xaxis, LLC. Before joining GroupM, Mr. Diamond was a member of the WPP plc family as the CFO for Healthworld Corporation (now called Ogilvy Health), where he took the company public and negotiated its sale to Cordiant Communications Group in 2000. He also served as CFO for National Medical Health Card Systems, Inc., a comprehensive pharmacy benefit management company. From 2008 to 2014, Mr. Diamond was the CFO for GroupM North America, where he established financial strategies and supervised all corporate accounting and financial activities for GroupM and its agencies. Earlier in his career, he held the positions of Vice President and Controller for Calvin Klein, Inc and as Senior Vice President and CFO for Medicis Pharmaceutical Corporation. Mr. Diamond holds a B.S. from the State University of New York, a Master of Science, Taxation degree from Pace University, and an MBA from Fordham.

Roby Joyce, MD, is the Laboratory and Medical Director of Precision Pathology Laboratory Services, a wholly owned subsidiary of bioAffinity Technologies, Inc., and President of Village Oaks Pathology Services (VOPS). Dr. Joyce is board-certified in anatomic and clinical pathology by the American Board of Pathology and is a Fellow in the College of American Pathologists. He is also board-certified in neurology by the American Board of Psychiatry and Neurology (Neurology) and is a Fellow in the American Academy of Neurology. He has served in various capacities at Northeast Methodist Hospital in San Antonio, including Chairman of the Board of Trustees from 1994-1995 and Chief of Staff of the Methodist Healthcare System from 2005-2006. Throughout a career in pathology that spans more than 40 years, he has been a highly regarded speaker at medical and scientific conferences, has served in leadership roles on dozens of professional organizations and committees, and has served as lead or co-author of numerous scientific articles.  Dr. Joyce received his medical degree from Louisiana State University in New Orleans. He completed an internal medicine internship at Fitzsimons Army Medical Center in Denver, his residency in neurology at the Letterman Army Medical Center Hospital in San Francisco and his residency in pathology at Brooke Army Medical Center in San Antonio. He is a retired US Army colonel.

Peter S. Knight is a Partner at Cyan Capital Partners, a Fund dedicated to helping new Fund managers and asset owners in the field of sustainable investing. Prior to that, Peter was a Founding Partner at Generation Investment Management, where he helped build, with his partners Al Gore and David Blood, a leading global sustainable investing firm with assets under management now exceeding $30 billion. Prior to his retirement from the firm in 2018, Mr. Knight held leadership positions within Generation IM, notably developing and overseeing the firm’s U.S. business.

Prior to Generation, Mr. Knight was a Managing Director of Met West Financial, an LA based asset management company. Mr. Knight started his career at the Antitrust Division of the US Department of Justice. From 1977 to 1989, he served as the Chief of Staff to Representative and later Senator Al Gore. He served as the General Counsel of Medicis Pharmaceutical and then started his law practice in where he represented the International Olympic Committee, the US Olympic Committee, and numerous Fortune 500 Companies. Mr. Knight has also served in senior positions on four Presidential campaigns including serving as the Campaign Manager for President Clinton’s 1996 re-election campaign.

Mr. Knight has extensive board experience in both the for-profit and non-profit sectors. He served on a number of public company Boards including Medicis, Par Pharmaceutical, Entremed (Casi), Healthworld, Whitman Education, Comsat and the Schroder Mutual Fund Board complex. Mr. Knight currently serves on the Fund Boards of Generation Investment Management and on the Board of Gratitude Railroad. His philanthropic efforts include serving as Chair of the Climate Museum and the Board of Emergent, a nonprofit intermediary to help stop deforestation on tropical forest nations.

He received a BA from Cornell University and a JD from the Georgetown Law School.

Dr. Platt brings 20 years of progressive leadership in genomics and molecular diagnostics, guiding teams in developing, validating, and commercializing more than 40 innovative, high-complexity molecular tests for US and global firms (both LDTs and IVDs). She served as Chief Operating Officer at PGDx (acquired by LabCorp) and Inivata (acquired by NeoGenomics) leading development and operationalization of liquid biopsy products and completing two M&A exits in 2021 for a combined value of nearly $1 Billion ($965M USD). As Chief Operating Officer at Inivata, Dr.Platt led the organization’s transition from research-stage through early commercialization, developing and launching two best-in-class liquid biopsy products, as well as establishing a $25 million equity investment with follow-on acquisition by NeoGenomics. As Vice President of Genomic Solutions at MPLN/Geneuity and Director of Advanced Sequencing at Quest Diagnostics, she introduced next generation sequencing (NGS) clinical assays and genomics products and line extensions.

Dr. Platt earned her Ph.D. in Molecular & Cellular Biology from Oregon State University and completed post-doctoral studies at the University of California, Berkeley. She is founder and CEO of BRIDGenomics, a molecular diagnostic laboratory consulting firm and serves on the boards of Pictor, Ltd. DxTerity Diagnostics, and bioAffinity.

Dr. Platt is passionate about leveraging her expertise in product development and clinical laboratory operations to provide accretive value to the boards and organizations she serves. She is an industry-recognized peer educator and speaker, holds multiple US and international patents and has authored numerous peer-reviewed publications. 

Mr. Rubin, a Certified Public Accountant, serves as a Managing Member of Masters Research Partners, LLC, an investment Fund of Hedge Funds that he co-founded in October 2000. Mr. Rubin began his career with Deloitte & Touche and later served as Managing Partner at Schissel, Rubin & Lehman, a New York based Certified Public Accounting firm. He has been involved in the investment business, including hedge funds, private equity and investment banking, for more than 20 years. Mr. Rubin is active in numerous charities as well as his Family’s foundation, and presently serves on the Board of Boca Raton Regional Hospital Foundation and the Finance committee of the Levitz Jewish Community Center, as well as serving as a Board Member for Family Promise of the Federation of South Palm Beach County. He graduated with a Bachelor of Science cum laude from SUNY at Buffalo, New York.

Ms. Zannes brings more than 30 years of executive-level management experience dedicated to defining and advancing company goals and overcoming obstacles impeding corporate success. Prior to her position at bioAffinity Technologies, Ms. Zannes founded The Zannes Firm focusing on strategic solutions for private industry in the medical, environmental and energy fields. In her current capacity as bioAffinity Technologies CEO and President, she has built a team of award-winning scientists and executives who are advancing breakthrough oncology-focused diagnostics and therapeutics.

Ms. Zannes was President of the Energy Recovery Council, the national trade group for the $10 billion waste-to-energy industry, and General Manager of ECOS Corporation, a subsidiary of Burlington Environmental. Ms. Zannes also served as a project manager at Wheelabrator Technologies, Inc. where she led project teams that developed, negotiated and financed the company’s renewable energy generation facilities. Ms. Zannes began her career as a journalist, working for Voice of America and the Associated Press. Before entering the business world, she served as a legislative aide specializing in energy policy and law for Congressman Charles Wilson (D-TX). She is licensed to practice law in New Mexico. She has been awarded Lifetime Achievement Awards by the American Society of Mechanical Engineers and the Earth Engineering Center Award from the WTE Council of Columbia University.

She is the co-founder of two engineering research centers at Columbia University. Ms. Zannes received her B.A. in Journalism from the University of New Mexico and her J.D. from the University of Puget Sound in Washington State.